Stockscreener 앱 받기
12.47
2.65%
-0.34
전일 마감가:
$12.81
열려 있는:
$12.81
하루 거래량:
1.33M
Relative Volume:
0.65
시가총액:
$711.85M
수익:
-
순이익/손실:
$-72.89M
주가수익비율:
-5.1529
EPS:
-2.42
순현금흐름:
$-68.47M
1주 성능:
-3.18%
1개월 성능:
-3.11%
6개월 성능:
+97.00%
1년 성능:
+60.90%
1일 변동 폭
$12.41
$12.81
1주일 범위
$12.41
$12.92
52주 변동 폭
$3.555
$13.29
Astria Therapeutics Inc Stock (ATXS) Company Profile
명칭
Astria Therapeutics Inc
전화
617-349-1971
주소
22 BOSTON WHARF ROAD, BOSTON
ATXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
12.47 | 731.26M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-17 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | TD Cowen | Buy |
| 2023-03-28 | 개시 | Evercore ISI | Outperform |
모두보기
Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스
Hedge Fund Bets: Is Astria Therapeutics Inc trading at a discount2025 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Why (ATXS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - Yahoo Finance
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® - GlobeNewswire
Why Astria Therapeutics Inc. stock could outperform in 20252025 Major Catalysts & Free Long-Term Investment Growth Plans - ulpravda.ru
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - PR Newswire
Growth Recap: Is Astria Therapeutics Inc stock in correction or buying zone2025 Trade Ideas & Consistent Profit Focused Trading Strategies - Bộ Nội Vụ
Astria Therapeutics (NASDAQ:ATXS) Reaches New 52-Week HighTime to Buy? - MarketBeat
Understanding Momentum Shifts in (ATXS) - Stock Traders Daily
Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward - MSN
JMP Securities Downgrades Astria Therapeutics (ATXS) - MSN
Patterns Watch: Is Astria Therapeutics Inc stock gaining market shareMarket Performance Summary & Capital Efficiency Focused Strategies - moha.gov.vn
Astria faces shareholder lawsuits over planned BioCryst merger - MSN
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Hold” by Brokerages - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment - MSN
(ATXS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Astria Therapeutics IncComplaints filed against Astria in New York Supreme CourtSEC filing - marketscreener.com
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger - TipRanks
Astria Therapeutics Merger with BioCryst Pharmaceuticals - TradingView — Track All Markets
Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-ATXS, MBCN, FMNB, and SEMR - The Malaysian Reserve
Why Astria Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Reactions & Accurate Entry/Exit Alerts - DonanımHaber
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR - Sahm
Astria Therapeutics Earnings Notes - Trefis
Astria Therapeutics (ATXS) price target decreased by 17.94% to 21.62 - MSN
Technical Reactions to ATXS Trends in Macro Strategies - Stock Traders Daily
FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com UK
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com
Astria Therapeutics, Inc. $ATXS Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS - MarketBeat
Affinity Asset Advisors LLC Purchases Shares of 300,000 Astria Therapeutics, Inc. $ATXS - MarketBeat
Will Astria Therapeutics Inc. stock gain from government policies2025 Market Overview & Verified Swing Trading Watchlists - Newser
Astria Therapeutics (NASDAQ:ATXS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Hold" from Analysts - MarketBeat
BioCryst’s Ongoing Boost: Buy or Watch? - StocksToTrade
Astria Therapeutics (NASDAQ:ATXS) Sets New 1-Year HighWhat's Next? - MarketBeat
Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - The Manila Times
BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative
BioCryst receives antitrust clearance for Astria acquisition - Investing.com
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-TCBX, RNA, ATXS, and FSUN - The Malaysian Reserve
Trading the Move, Not the Narrative: (ATXS) Edition - news.stocktradersdaily.com
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Astria Therapeutics: Updating Target Price, BioCryst Deal Expected To Go Through, Hold - Seeking Alpha
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN - The Malaysian Reserve
Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
(ATXS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Will Astria Therapeutics Inc. stock split again soonJuly 2025 Summary & High Yield Equity Trading Tips - newser.com
Astria Therapeutics Inc (ATXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):